Sign In
Buy HOTH
$0.792
+0.0013 (+0.164%)
At Close: Jul 31, 2026
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET.
Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate
12:07pm, Wednesday, 22'nd Apr 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET.
Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study
02:18pm, Tuesday, 21'st Apr 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership
Hoth Therapeutics Announces Additions to its Board of Directors
12:00pm, Friday, 17'th Apr 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors. The C
RemeGen candidate Fast Track'd for lupus
03:13pm, Wednesday, 15'th Apr 2020
The FDA has signed off on Fast Track status for Yantai, China-based RemeGen's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE).RC18 (telitacicept) is a recombinant TACI-F
Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines
01:13pm, Wednesday, 15'th Apr 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest o
Hoth Therapeutics Commences Next Phase of VNLG-152 Study
12:00pm, Thursday, 09'th Apr 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or R
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the full
TLRY, HEXO among premarket gainers
01:16pm, Friday, 27'th Mar 2020
Astrotech (NASDAQ:ASTC) +59% as breathTest-1000 confirmed to detect lung disease metabolites at parts per billion.MFA Financial (NYSE:MFA) +26%.Hoth Therapeutics (NASDAQ:HOTH) +22% on agreement wi
More Covid-19 actions - healthcare
12:12pm, Friday, 27'th Mar 2020
Humanigen (OTCQB:HGEN) has submitted a protocol synopsis to the FDA related to its planned Phase 3 study of lenzilumab for the prevention and treatment of cytokine storm in COVID-19 patients.Hoth Ther
HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ: HOTH) (previously r
Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More
02:34pm, Wednesday, 25'th Mar 2020
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Be
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
